Introduction
One of the arenaviruses infecting humans is the lymphocytic choriomeningitis virus (LCMV), which is a segmented negative-sense single-stranded RNA virus within the Mammarenavirus genus, family Arenaviridae. LCMV genome is composed of two RNA segments: a large segment (L-segment) and a small segment (S-segment). The L-segment is a highly conserved segment that encodes for the L-protein and Z-protein, while the S segment encodes for the nucleoprotein (NP) and glycoprotein complex (GPC) [Reference Lee1]. Humans are thought to acquire LCMV infection through direct contact with rodents, rodent bites, or mucosal exposure to aerosols contaminated with rodent excreta. In humans, the clinical picture of LCMV infection ranges from asymptomatic to severe manifestations, such as aseptic meningitis, severe systemic infections in immunocompromised persons, and congenital abnormalities [Reference Bonthius2]. Typically, a biphasic disease can occur with unspecific first-phase symptoms including flu-like illness with fever, followed by a second phase with more neurological symptoms mimicking, for example, tick-borne encephalitis virus (TBEV) infection [Reference Stone3]. Immunosuppressed individuals and transplant recipients are the most vulnerable to LCMV infection, in addition to pregnant individuals, who are prone to fatal infections [Reference Fischer4–Reference Delaine6]. For LCMV, the common house mouse (Mus musculus) is the reservoir host. However, serological data indicate that the LCMV or LCMV-like viruses can also infect pet mice, hamsters (Mesocricetus auratus), forest voles (Microtus agrestis), and Guinea pigs (Cavia porcellus) [Reference Stone3, Reference Martínez Peralta7–Reference Biggar9]. Furthermore, LCMV-like virus RNA was detected in wood mice (Apodemus sylvaticus) in Spain, suggesting that a new lineage of LCMV or a LCMV-like virus circulates among wood mice [Reference Ledesma10]. In Australia, during an investigation of a small cluster of transplant-related fatal cases, an LCMV variant, Dandenong virus, was discovered [Reference Palacios11].
Studies conducted in the USA in 1953 and 1992 reported the presence of antibodies against LCMV in 8% of neuroinvasive patients and 5.1% of the healthy, respectively [Reference Adair, Gauld and Smadel12, Reference Stephensen13]. In Argentina, LCMV is endemic in some cities, and there are a few studies reporting LCMV seroprevalence rates of 2.3% and 1–3.6% in the 1990s and between 1998 and 2003, respectively [Reference Ambrosio14, Reference Riera15]. In Europe, Tagliapietra et al. [Reference Tagliapietra16] showed that the seroprevalence increased from 2.5% to 7% among Italian forest workers between 2002 and 2015 in the province of Trento. Another study from France showed that only 1.7% of the population was positive for anti-LCMV antibodies [Reference Lledó17]. However, on Vir Island in Croatia, a high seroprevalence for LCMV (36%) has been reported [Reference Dobec18]. In this Croatian study, the IFA cut-off was relatively lower, which might have affected the results. However, in some countries, LCMV may be more prevalent. In Finland, a seroprevalence of 5% has been previously reported for LCMV [Reference Fevola19], and this is in line with most European countries. In addition to human data, there is evidence of arenavirus-reactive antibodies in Finnish field voles (2.4%) [Reference Forbes8], but no LCMV or other arenavirus nucleic acids have been detected so far, in humans or rodents, in Finland. Currently, there are no studies on screening of pet rodents or other wild rodents, while screening studies on field voles in Finland are available. Interestingly, using next-generation sequencing (NGS), Sanchez Romano et al. (2021) [Reference Sánchez Romano20] detected reads similar to Arenaviridae from tundra reindeer (Rangifer tarandus tarandus) in northern Finland. In this study, we aimed to detect arenavirus nucleic acids in available human samples [serum and cerebrospinal fluid (CSF)] and to study LCMV or LCMV-like virus seroprevalence in different geographical regions of Finland. Previously, 400 patients suspected of having a central nervous system infection were examined for LCMV infections [Reference Fevola19], but in this study, we aimed to study samples with a wider distribution using samples taken from suspected tick-borne encephalitis (TBE) cases, as the disease profile mimics LCMV infection, and to detect the LCMV from these human samples. Furthermore, we aimed to highlight some factors that are associated with varied degrees of arenavirus seroprevalence between regions.
Materials and methods
Samples
As symptoms of LCMV infection can mimic those of TBEV infection, samples sent to the Helsinki University Hospital (Diagnostic Center, HUS, Helsinki, Finland) for anti-TBEV antibody detection could be considered potentially enriched for LCMV. All serum and CSF samples from the high season of TBE – June to November 2018 (total of 6 months) – which were sent for screening of anti-TBEV antibodies to the Diagnostic Center (HUS, Helsinki, Finland), were included in this study, including in a total of 976 serum samples from 867 individuals aged 1–89 (mean 46) years (Table 1). Of these 867 individuals, 222 had corresponding CSF samples available (a total of 227 CSFs), and all of them were included in this study. All samples were recoded and treated anonymously. Information on gender was not available. This study was approved by the Research Administration of the Helsinki University Hospital (HUS/32/2018, HUS/157/2020, HUS/151/2022). Five different geographical regions following the borderlines of Finland’s hospital districts in 2018 were included in this study: north, east, west, south, and Åland (Figure 1).
Age distribution and population parameters within the five regions
a Reference to the database concerning the population data [24].
Map of Finland illustrating the regions, total population (above line), and number of individuals included in the study (below line).
Immunofluorescence assay
All 867 individuals (976 serum samples) were screened for anti-LCMV IgG antibodies using immunofluorescence assay (IFA), as described previously [Reference Fevola19, Reference Kallio-Kokko21, Reference Jääskeläinen22]. The IFA method is based on the LCMV Armstrong strain-infected Vero E6 cells, and a serum dilution of 1:20 was used. There are both LCMV-infected and non-infected Vero-E6 cells in all wells of the IFA slide. The non-infected cells are in-well internal controls for the detection of unspecific reactivities. Our method is not only specific to LCMV but is also based on whole LCMV, enabling the detection of LCMV-like viruses. After the detection of anti-LCMV IgG antibodies, all the positive samples for anti-LCMV IgG were tested for anti-LCMV IgM antibodies, as described previously [Reference Fevola19]. All the samples were stored at −80 °C until use. Antibodies were not screened from the CSF samples.
Detection of viral RNA and sequencing
Nucleic acids were extracted from 976 serum samples using the MagNA Pure LC system, and the Total Nucleic Acid Kit (Roche) and NucliSENS easyMAG (bioMérieux) were used for the 227 CSF samples following the manufacturers’ instructions. In addition, the Qiagen Viral Mini Kit was used for the re-extraction of 49 serum and 19 CSF samples. The extracted nucleic acids were used as templates in RT-PCR experiments targeting the conserved L gene of Old-World arenaviruses using primers designed by Vieth et al. [Reference Vieth23]. The RT-PCR-mix included the Invitrogen SuperScript®III One-Step RT-PCR System with Platinum®Taq DNA Polymerase (Invitrogen, Carlsbad, CA) and primers of 320 nm LVL_3359D, 320 nm LVL_3359G, 480 nm LVL_3754A, and 480 nm LVL_3754D with 4 μL of template in a total volume of 20 μL. RT-PCR included a 30-min reverse transcription phase at 50 °C, followed by 2 min at 94 °C, and 45 cycles of 20 sec at 94°C, 30 at sec 55°C and 1 min at 72 °C, with a final elongation step of 5 min at 72 °C. PCR products were visualized using agarose gel electrophoresis (2.2%), and the PCR products [size over 350 base pairs (bp)] from patient samples, in addition to the positive control (LCMV Armstrong strain), were purified using the QuickStep™ 2 PCR Purification Kit (EdgeBio), followed by sequencing at the Diagnostic Center (HUS, Helsinki, Finland) using the Sanger sequencing platform.
Statistical analysis
Statistical analysis was carried out using IBM SPSS Statistics version 28 [24]. Differences between independent groups of continuous variables were tested using the independent-samples Mann–Whitney U test (two groups) or independent-samples Kruskal–Wallis test (multiple groups). Normality of the data was tested using the Shapiro–Wilk test, histograms, and Q-Q plots. Categorical data were tested using the Fisher–Freeman–Halton exact test. P-values below 0.05 were considered statistically significant, and confidence intervals were calculated using the Wilson method. Population data were acquired from Statistics Finland’s free-of-charge databases [25].
Results
No arenavirus nucleic acids were detected from 976 serum and 227 CSF samples studied. Although some PCR products were detected, when sequenced, no LCMV sequences were detected among the tested samples. In addition, no seroconversions were detected from paired serum samples taken from a total of 60 individuals; all were either negative or positive for anti-LCMV IgG antibodies in both paired samples. All anti-LCMV IgG-positive samples were negative for anti-LCMV IgM.
The overall LCMV seroprevalence was 4.5% (95% CI 3.3–6.1%) (June–November 2018). The highest LCMV seroprevalence was detected among individuals of age group I (40–59 years) (5.2%) and the lowest in age group IV (60 years or older) (3.8%) (Table 2). LCMV seroprevalences detected in individuals of age groups I and II (under the age of 20 years and 20–39 years) were 4.9% and 4.4%, respectively (Table 2). The LCMV seroprevalence was slightly higher in the north region (6.7%), followed by Åland (5.6%) and south regions (5.1%), respectively (Table 2). Statistical analysis showed slight differences in the age distribution between regions (Supplementary Figure 1, Supplementary Table 1 available on the Cambridge Core website), with the median age group being 40–60 years (p = 0.001 between south and east and north and east). Overall, the difference between age and IgG status was not statistically significant (p-value = 0.465), but there were some variations in the seroprevalence between different regions. Anti-LCMV antibodies were detected in all the regions, with the highest percentage in the north region and the lowest in the east region.
Overall seroprevalence of arenavirus-reactive antibodies detected in human samples according to their age groups and geographical regions. The IFA seropositive shown in percentages
Discussion
In this study, we performed a survey for LCMV prevalence in humans using molecular and serological assays. A total of 867 individuals were screened for LCMV or LCMV-like virus nucleic acids and LCMV-reactive antibodies. In contrast to a previous study [Reference Fevola19], we screened samples originating from cases suspected of having TBE with altogether more geographical variation within Finland. However, data from these individuals do not represent the general population, and only suggestions can be drawn. The overall seroprevalence detected in our study (4.5%) is in line with that in the previous study (5%) [Reference Fevola19]. In terms of geographical distribution, LCMV seroprevalence varied between the regions, with northern Finland having the highest seroprevalence (6.7%) and eastern Finland the lowest (0.8%) (Supplementary Figure 1). The highest LCMV seroprevalence in northern Finland is likely associated with unidentified factors; for instance, exposure to different host species might be high. For example, Sanchez Romano et al. (2021) [Reference Sánchez Romano20] reported that the most abundant reads were found for Arenaviridae samples using NGS that were taken from tundra reindeer of northern Finland. This raises the following question: Is there an unknown arenavirus in reindeer, or Is this something detected from the reindeer genome? There were no LCMV–host (M. musculus) observations in the north region during the study period (Figure 2). Interestingly, the highest LCMV seroprevalence was detected in the younger age group. This highlights the likelihood of divergent species acting as hosts for LCMV or LCMV-like viruses. In one study conducted in Finland, the presence of anti-LCMV antibodies has also been reported in Finnish field voles (M. agrestis) [Reference Forbes8]. Unfortunately, no other studies are available from Finland.
Mus musculus observations in Finland. (a) Observation of M. musculus in Finland from 1854 to 2022. (b) Observation of M. musculus in Finland during the study period June–November 2018. Finnish Biodiversity Info Facility [Reference Alburkat29].
The detection of LCMV-like arenavirus in small mammals other than M. musculus has been reported worldwide. In Spain, LCMV RNA was detected in wood mice (A. sylvaticus), and the results revealed a new lineage of LCMV, indicating the presence of a newly identified LCMV-like virus [Reference Ledesma10]. Probably, there might be many more arenaviruses to be found in rodents. Indeed, antibodies against LCMV or LCMV-like arenavirus could be detected in different rodent species, but without viral sequence data, it is difficult to speculate whether it is the LCMV or a LCMV-like virus. As the immunofluorescence method used in this study is based on the whole virus antigen, cross-reactions to closely related viruses might have occurred. Moreover, cross-reactions could happen between Old-World and New-World arenaviruses; for instance, mice immunized with Old-World arenavirus (Lassa and Mopeia viruses) showed antibodies cross-reactive to New-World arenaviruses (South American arenaviruses) [Reference Ruo26].
In general, the estimated time of the viremia in LCMV patients is approximately 2 weeks after the first symptoms (first phase). Antibodies that can neutralize the virus typically develop 2–6 weeks after the onset of symptoms and can persist for a period of 6 months to 5 years [Reference Wilson, Peters, Tselis and Booss27]. However, Bond et al. (2013) [Reference Bond28] have suggested that anti-Lassa virus IgG antibodies can persist even up to 40 years. Virus titres in the CSF are lower and are present for a shorter time, which makes the detection of the virus difficult. Nevertheless, molecular methods carried out on CSF samples are still considered the most reliable method for LCMV detection, and LCMV RNA from CSF was characterized in previous studies [Reference Fischer4, Reference Alburkat29]. Serology can only point out potential recent infection [Reference Stone3]; the sample is usually positive for both anti-LCMV IgG and IgM antibodies. We also looked for acute infections by searching for seroconversions by paired samples but found none.
The house mouse (M. musculus) is considered to be the host for LCMV, but there is evidence that other rodents can also have anti-LCMV (or anti-LCMV-like virus) antibodies [Reference Forbes8], [Reference Lledó17]. In Finland, the range of M. musculus seems to be diminishing, and nowadays, the species is reported only occasionally by the Finnish Biodiversity Info Facility [30], which is an open-access data source that provides data on observations of certain species in Finland. However, these data cannot be considered true markers of population sizes in Finland. Curiously, in this study, LCMV seroprevalence is a little higher in younger human age groups. Based on our study and the knowledge of decreased M. musculus observations in Finland, it seems that those in age group III (40–59 years) and young people were in contact with the virus at the same level or even more than older people, raising questions on the source of infection (rodent) or contact with the LCMV or LCMV-like viruses. But as our data are not based on the general population, more data are needed. However, the precise arenavirus type or types present in Finland remains unconfirmed [Reference Dobec18]. In future, studies on different Finnish rodents, perhaps including pet rodents like hamsters, should be carried out to discover whether there are some LCMV-related viruses.
Conclusion
In this study, a survey was performed to detect arenavirus nucleic acids in humans and to study LCMV seroprevalence in different geographical regions of Finland. The results demonstrate that anti-LCMV antibodies were fairly common, and in this study, there were more seropositive cases in younger age groups than in old age groups. The coincidence of the diminishing range of M. musculus and LCMV seroprevalence in young age groups suggests the exposure of an LCMV-like virus in Finland.
Supplementary material
The supplementary material for this article can be found at http://doi.org/10.1017/S0950268824000128.
Data availability statement
The data that support the findings of this study are available upon request.
Acknowledgements
We thank Petra Harinen and Eevaleena Vaittinen (Metropolia University of Applied Sciences, Helsinki, Finland; PCR assays), Eetu Sironen (University of Helsinki, Helsinki, Finland; IFA), Mira Utriainen (University of Helsinki; for making the IFA slide), Ruut Uusitalo (University of Helsinki; for designing the rodent observations map), and Janita Ahokas (HUS Diagnostic Center, Helsinki, Finland; IFA) for their excellent technical assistance.
Author contribution
A.J.J., H.A., and T.S. were involved in the conceptualization of the study. A.J.J., E.P., and H.A. contributed to data curation. A.J.J., E.P., H.A., and J.V. were involved in formal analysis. A.J.J., O.V., and T.S. were involved in funding acquisition. A.J.J., H.A., and E.P. contributed to investigation. A.J.J. and H.A. contributed to methodology. A.J.J. and T.S. were involved in project administration. A.J.J., H.A., and T.S. contributed to resources. J.V. contributed to software. A.J.J. and T.S. supervised the study. A.J.J. was involved in study validation. E.P. and J.V. contributed to visualization. A.J.J., H.A., and T.S. were involved in the writing of the original draft. A.J.J., E.P., H.A., J.V., O.V., and T.S. contributed to the writing, reviewing, and editing of the manuscript.
Funding statement
This work was financially supported by the HUS Diagnostic Center (Helsinki University Hospital, Helsinki, Finland; TYH2019263 and TYH2021110).
Competing interest
The authors declare none.
Ethical standard
The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation. This study was approved by the Research Administration of the Helsinki University Hospital (HUS/32/2018, HUS/157/2020, HUS/151/2022).
Open access
